Fiercely Pursuing and Delivering Therapies

Dedicated to quality and driven by excellence, we are committed to improving the lives of patients worldwide.

Creating Hope and New Opportunities

Our pipeline of cell therapies includes agents across hematologic and solid tumors. We focus on diseases that are considered intractable and incurable.

Transforming the World of Oncology and Medicine

We are a 1,000+ team driven by our passion for developing cutting-edge cell therapies.

Our news

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

Nov 21, 2022

Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Nov 03, 2022

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Sep 27, 2022

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

Sep 15, 2022

Legend Biotech Announces Participation in Upcoming Investor Conferences

Aug 19, 2022

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

Aug 05, 2022

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

Aug 04, 2022

Legend Biotech Corporation Announces Proposed Public Offering

Jul 25, 2022

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Jun 04, 2022

Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

Jun 03, 2022

Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

Jun 01, 2022

Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

May 26, 2022

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma with Updated Data from BCMA CAR-T Studies at 2022 ASCO and EHA

May 18, 2022

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

May 09, 2022

Legend Biotech Announces Participation in Upcoming Investor Conferences

May 06, 2022

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

Apr 21, 2022

Legend Biotech Announces Appointment of Global Head of Research and Early Development

Apr 01, 2022

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Mar 25, 2022

Flanders Investment and Trade Names Legend Biotech Newcomer of the Year

Mar 23, 2022

Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Mar 18, 2022

CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Feb 28, 2022

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

Feb 18, 2022

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

Feb 15, 2022

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

Feb 11, 2022

Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Jan 04, 2022

Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

Dec 30, 2021

Legend Biotech Corporation Announces Pricing of Public Offering

Dec 16, 2021

Legend Biotech Corporation Announces Proposed Public Offering

Dec 14, 2021

Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma

Dec 13, 2021

Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting

Dec 07, 2021

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory

Dec 06, 2021

Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights

Nov 16, 2021

Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH

Nov 04, 2021

Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel

Nov 01, 2021

Legend Biotech to Host R&D Day on October 18, 2021

Sep 22, 2021

Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

Sep 13, 2021

Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

Aug 30, 2021

Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights

Aug 23, 2021

Legend Biotech Announces Advancement of Global Manufacturing Infrastructure

Jun 22, 2021

Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings

Jun 01, 2021

U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma

May 26, 2021

Legend Biotech to Present at the Jefferies Virtual Healthcare Conference

May 25, 2021

Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights

May 18, 2021

Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings

May 12, 2021

Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Apr 30, 2021

Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update

Mar 18, 2021

Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call

Mar 10, 2021

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020

Feb 19, 2021

Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Feb 01, 2021

Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA SeekingApproval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Dec 21, 2020

Legend Biotech to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Dec 15, 2020

Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous AntiCD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

Dec 14, 2020

Legend Biotech Added to the NASDAQ Biotechnology Index

Dec 14, 2020

Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

Dec 05, 2020

Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors

Dec 03, 2020

Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting

Nov 24, 2020

Legend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang Zhang

Nov 23, 2020

Legend Biotech Reports Third Quarter 2020 Financial Results

Nov 16, 2020

Legend Biotech Announces Leadership Transition

Nov 09, 2020

Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Nov 05, 2020

Legend Biotech to Participate in the Jefferies Virtual Cell Therapy Summit

Sep 28, 2020

Legend Biotech Names Current Chief Financial Officer, Ying Huang, as Interim CEO

Sep 21, 2020

Legend Biotech to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

Sep 01, 2020

Legend Biotech Reports Second Quarter 2020 Financial Results

Aug 28, 2020

The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy

Aug 05, 2020

Legend Biotech Announces Chief Executive officer Transition

Aug 02, 2020

Legend Biotech Announces Preliminary Results for First Half of 2020

Aug 02, 2020

Legend Biotech Announces Three New Appointments to the Board of Directors

Jun 09, 2020

Legend Biotech Corporation Announces Closing of Initial Public Offering

Jun 09, 2020

Legend Biotech Corporation Announces Pricing of Initial Public Offering

Jun 05, 2020

Updated Results from Phase 1b/2 Study of BCMA CAR-T Therapy JNJ-4528 Shows Early, Deep and Durable Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

May 13, 2020

Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing Agreement

May 04, 2020

Legend Biotech Raises $150.5 Million in Series A Preferred Financing To Advance its Oncology Pipeline and Platform

Apr 01, 2020

Legend Biotech Announces Milestone Payment Achieved from the LCAR-B38M CAR-T Collaboration with Janssen

Jan 28, 2020

Updated Data from LEGEND-2, a Phase 1/2 Open-label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Long-term Responses, Safety Profile, and Complete Response Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myelomama

Dec 09, 2019

Initial Data from Phase 1b/2 Study of BCMA-Directed CAR-T Cell Therapy JNJ-4528 Show Early and High Responses in Advanced Relapsed or Refractory Multiple Myeloma

Dec 07, 2019

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for
JNJ-68284528, an Investigational BCMA CAR-T Cell Therapy

Dec 06, 2019

Legend Biotech Announces Data Presentations at ASH 2019 for JNJ-68284528 (JNJ-4528)/LCAR-B38M, an Investigational B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR)-T Cell Therapy being Studied in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Nov 06, 2019

Legend Biotech Announces Milestones Achieved from the LCAR-B38M CAR-T Collaboration with Janssen

Aug 05, 2019

New Data from LEGEND-2 Study of LCAR-B38M BCMA CAR-T Therapy Show High Overall Response in Patients with Advanced Relapsed or Refractory Multiple Myeloma

Apr 15, 2019

European Medicines Agency Grants Janssen PRIME Designation for JNJ-68284528 (LCAR-B38M), an Investigational BCMA CAR-T Therapy Discovered by Legend Biotech

Apr 03, 2019

Legend Biotech Ireland, Ltd. celebrates the official opening of its European headquarters in Dublin, Ireland

Mar 05, 2019

Legend Biotech USA, Inc. joins The American Society for Blood and Marrow Transplantation (ASBMTTM) Corporate Council

Feb 01, 2019

ASH 2018: Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma

Dec 03, 2018

Legend Biotech Chairman Frank Zhang awarded 2018 Person of the Year from China Healthcare Summit

Nov 14, 2018

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

May 30, 2018

Nanjing Legend formally received the permission of a clinical trial granted by the CFDA with respect to LCAR-B38M CAR-T for autologous infusion

Mar 13, 2018

Legend Biotech Announces Closing of Global Strategic LCAR-B38M CAR-T Cell Immunotherapy Collaboration with Janssen

Dec 22, 2017

Legend Biotech Corporation Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Aug 26, 2022

Learn about us

Explore our technologies

We are technology agnostic in targeting hematologic malignancies and solid tumors. We are exploring 4 different technologies to help treat disease.

Meet our leadership team

Our leaders bring significant expertise from some of the world’s largest pharma companies.

Understand our capabilities

We are an end-to-end cell therapy company. Our capabilities extend from discovery to commercialization.

Work with us

We offer a variety of career choices that support the development of novel therapies.

Our pipeline

Our pipeline is comprised of investigational agents and innovative technologies in personalized medicine. We are devoted to exploring the potential of cell therapies to treat diseases that are considered intractable and incurable, including hematological malignancies and solid tumors.

LEARN MORE